Categories: The Charlton Centre

New Pain Pathways in Osteoarthritis

New pain pathways are being identified in osteoarthritis. This is the most common type of arthritis in North America.  Keeping active and weight loss are important in slowing the progression of osteoarthritis.  For some people, joint damage can be significant and yet they may not be able to have joint replacement surgery.  Many new treatments are being researched to address pain being generated by the joints specifically.  One area of research is aimed at reducing NGF (nerve growth factor).  This type of treatment may also be of great help in reducing bone cancer pain, diabetic neuropathy, low back pain and interstitial cystitis.  Stay tuned as this research moves forward.


Our pharmacist, Carolyn Whiskin, recently returned from The American College of Rheumatology Conference, the largest international meeting held for rheumatology. Over 15,000 health professionals from around the world specializing in research and the care of people with arthritis were in attendance. Today’s blog post is one several with information Carolyn learned at the Conference.

admin

Recent Posts

Bimzelx Now Approved for Hidradenitis Suppurativa (HS)

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition that can be very painful and…

4 weeks ago

Happy Holidays from Charlton Health

As the year comes to a close, we wish you a joyful holiday season filled…

1 month ago

Winrevair: A New Treatment Option for Pulmonary Arterial Hypertension (PAH)

Pulmonary arterial hypertension occurs when there is increased pressure in the small blood vessels that…

2 months ago

New Biologic Treatment for PMR (Polymyalgia Rheumatica)

Polymyalgia rheumatica (PMR) is an inflammatory condition that causes widespread joint and muscle pain along…

2 months ago

Expanded Protection: RSV Vaccine Now Approved for More Adults

Respiratory Syncytial Virus (RSV) is a common virus that can cause serious lung infections, particularly in…

3 months ago

Rinvoq: A New Oral Option for Giant Cell Arteritis

Health Canada has recently approved Rinvoq (upadacitinib) for adults living with Giant Cell Arteritis (GCA). Rinvoq…

3 months ago